Kalos Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-23,900
| Closed | -$256K | – | 54 |
|
|
2022
Q2 | $256K | Buy |
23,900
+450
| +2% | +$4.82K | 0.34% | 96 |
|
|
2022
Q1 | $381K | Sell |
23,450
-1,909
| -8% | -$31K | 0.26% | 90 |
|
|
2021
Q4 | $340K | Buy |
25,359
+1,659
| +7% | +$22.2K | 0.09% | 208 |
|
|
2021
Q3 | $318K | Sell |
23,700
-350
| -1% | -$4.7K | 0.09% | 211 |
|
|
2021
Q2 | $395K | Hold |
24,050
| – | – | 0.16% | 162 |
|
|
2021
Q1 | $260K | Buy |
24,050
+250
| +1% | +$2.7K | 0.08% | 239 |
|
|
2020
Q4 | $177K | Sell |
23,800
-1,000
| -4% | -$7.44K | 0.08% | 231 |
|
|
2020
Q3 | $89K | Buy |
24,800
+5,850
| +31% | +$21K | 0.04% | 219 |
|
|
2020
Q2 | $90K | Hold |
18,950
| – | – | 0.04% | 206 |
|
|
2020
Q1 | $37K | Buy |
+18,950
| New | +$37K | 0.02% | 200 |
|
|
2019
Q4 | – | Sell |
-18,950
| Closed | -$53K | – | 205 |
|
|
2019
Q3 | $53K | Buy |
+18,950
| New | +$53K | 0.02% | 191 |
|
|
2019
Q2 | – | Sell |
-27,443
| Closed | -$223K | – | 196 |
|
|
2019
Q1 | $223K | Sell |
27,443
-1,257
| -4% | -$10.2K | 0.14% | 129 |
|
|
2018
Q4 | $251K | Sell |
28,700
-2,800
| -9% | -$24.5K | 0.12% | 152 |
|
|
2018
Q3 | $241K | Sell |
31,500
-1,000
| -3% | -$7.65K | 0.13% | 129 |
|
|
2018
Q2 | $156K | Hold |
32,500
| – | – | 0.07% | 183 |
|
|
2018
Q1 | $156K | Sell |
32,500
-1,000
| -3% | -$4.8K | 0.09% | 109 |
|
|
2017
Q4 | $164K | Buy |
+33,500
| New | +$164K | 0.08% | 196 |
|